JP5511379B2 - Ｃｇｒｐレセプターアンタゴニスト - Google Patents
Ｃｇｒｐレセプターアンタゴニスト Download PDFInfo
- Publication number
- JP5511379B2 JP5511379B2 JP2009520862A JP2009520862A JP5511379B2 JP 5511379 B2 JP5511379 B2 JP 5511379B2 JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009520862 A JP2009520862 A JP 2009520862A JP 5511379 B2 JP5511379 B2 JP 5511379B2
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- optionally substituted
- ring
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C1(C(C)C)I(C)**(*)C1=O Chemical compound C*C1(C(C)C)I(C)**(*)C1=O 0.000 description 11
- YIROYDNZEPTFOL-UHFFFAOYSA-N CC(C)(C(N1)=O)NC1=O Chemical compound CC(C)(C(N1)=O)NC1=O YIROYDNZEPTFOL-UHFFFAOYSA-N 0.000 description 1
- AXAZXVMDVJERLV-UHFFFAOYSA-N CC(C=CN1)(C1=O)I Chemical compound CC(C=CN1)(C1=O)I AXAZXVMDVJERLV-UHFFFAOYSA-N 0.000 description 1
- DQFMPTUTAAIXAN-UHFFFAOYSA-N CC1(C)N=CNC1=O Chemical compound CC1(C)N=CNC1=O DQFMPTUTAAIXAN-UHFFFAOYSA-N 0.000 description 1
- KHSLZRDCIFHSFK-UHFFFAOYSA-N CCC(C(CC1CC=O)=O)Sc2c1cccc2 Chemical compound CCC(C(CC1CC=O)=O)Sc2c1cccc2 KHSLZRDCIFHSFK-UHFFFAOYSA-N 0.000 description 1
- SNQITZSBRUBYDV-UHFFFAOYSA-N CCC(C)(C(C)=O)c1c(C)[o]cc1 Chemical compound CCC(C)(C(C)=O)c1c(C)[o]cc1 SNQITZSBRUBYDV-UHFFFAOYSA-N 0.000 description 1
- QPRYITWQXGNIDX-UHFFFAOYSA-N CCC1c(cccc2)c2SCC1=O Chemical compound CCC1c(cccc2)c2SCC1=O QPRYITWQXGNIDX-UHFFFAOYSA-N 0.000 description 1
- RSHRTHALPSIWMA-UHFFFAOYSA-N Nc1cc(CC(C2)(C(N3)=O)NC3=O)c2cc1 Chemical compound Nc1cc(CC(C2)(C(N3)=O)NC3=O)c2cc1 RSHRTHALPSIWMA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83239706P | 2006-07-21 | 2006-07-21 | |
| US60/832,397 | 2006-07-21 | ||
| PCT/US2007/016559 WO2008011190A1 (en) | 2006-07-21 | 2007-07-23 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544618A JP2009544618A (ja) | 2009-12-17 |
| JP2009544618A5 JP2009544618A5 (https=) | 2011-08-18 |
| JP5511379B2 true JP5511379B2 (ja) | 2014-06-04 |
Family
ID=38754729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520862A Expired - Fee Related JP5511379B2 (ja) | 2006-07-21 | 2007-07-23 | Ｃｇｒｐレセプターアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7842686B2 (https=) |
| EP (1) | EP2049532B1 (https=) |
| JP (1) | JP5511379B2 (https=) |
| CN (1) | CN101516875A (https=) |
| AT (1) | ATE469895T1 (https=) |
| AU (1) | AU2007275577A1 (https=) |
| CA (1) | CA2658573A1 (https=) |
| DE (1) | DE602007006961D1 (https=) |
| ES (1) | ES2343481T3 (https=) |
| WO (1) | WO2008011190A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY153249A (en) | 2005-11-14 | 2015-01-29 | Rinat Neuroscience Corp | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CA2650932C (en) | 2006-05-09 | 2013-01-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| DK2227257T3 (da) | 2008-01-07 | 2013-09-30 | Salutaris Medical Devices Inc | Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| DK2265288T3 (en) | 2008-03-04 | 2016-06-06 | Labrys Biologics Inc | Methods for the treatment of inflammatory pain |
| CA2716424C (en) | 2008-03-04 | 2015-04-28 | Pfizer Limited | Methods of treating chronic pain |
| CA2715151A1 (en) * | 2008-03-28 | 2009-10-01 | Merck Sharp & Dohme Corp. | Monocyclic cgrp receptor antagonists |
| CA2735821A1 (en) * | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Monocyclic amide cgrp receptor antagonists |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| KR101519192B1 (ko) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법 |
| NZ717704A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| AU2012258980B8 (en) | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| PE20161439A1 (es) | 2014-03-21 | 2017-01-26 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CN113227140A (zh) | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
| US20250084044A1 (en) * | 2022-01-14 | 2025-03-13 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205293B2 (en) * | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| CA2519475A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
| CA2518830A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| AU2004221891B2 (en) * | 2003-03-14 | 2009-11-19 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirohydantoin CGRP receptor antagonists |
| JP4673296B2 (ja) * | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | アリールスピロヒダントインｃｇｒｐ受容体拮抗物質 |
| ATE518852T1 (de) * | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| CA2579847A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| CA2582593A1 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
-
2007
- 2007-07-23 JP JP2009520862A patent/JP5511379B2/ja not_active Expired - Fee Related
- 2007-07-23 EP EP07796984A patent/EP2049532B1/en not_active Not-in-force
- 2007-07-23 AU AU2007275577A patent/AU2007275577A1/en not_active Abandoned
- 2007-07-23 CN CNA2007800342187A patent/CN101516875A/zh active Pending
- 2007-07-23 CA CA002658573A patent/CA2658573A1/en not_active Abandoned
- 2007-07-23 DE DE602007006961T patent/DE602007006961D1/de active Active
- 2007-07-23 WO PCT/US2007/016559 patent/WO2008011190A1/en not_active Ceased
- 2007-07-23 ES ES07796984T patent/ES2343481T3/es active Active
- 2007-07-23 AT AT07796984T patent/ATE469895T1/de not_active IP Right Cessation
-
2009
- 2009-01-21 US US12/356,745 patent/US7842686B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2049532B1 (en) | 2010-06-02 |
| US7842686B2 (en) | 2010-11-30 |
| ES2343481T3 (es) | 2010-08-02 |
| EP2049532A1 (en) | 2009-04-22 |
| DE602007006961D1 (de) | 2010-07-15 |
| JP2009544618A (ja) | 2009-12-17 |
| ATE469895T1 (de) | 2010-06-15 |
| CA2658573A1 (en) | 2008-01-24 |
| US20090186882A1 (en) | 2009-07-23 |
| AU2007275577A1 (en) | 2008-01-24 |
| CN101516875A (zh) | 2009-08-26 |
| WO2008011190A1 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5511379B2 (ja) | Ｃｇｒｐレセプターアンタゴニスト | |
| JP4673294B2 (ja) | 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質 | |
| US7834000B2 (en) | CGRP receptor antagonists | |
| RU2308458C2 (ru) | Антагонисты рецептора cgrp | |
| JP4673295B2 (ja) | 単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質 | |
| JP5382799B2 (ja) | Ｃｇｒｐ受容体アンタゴニスト | |
| JP4705922B2 (ja) | Ｃｇｒｐ受容体拮抗薬 | |
| JP2013518046A (ja) | 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 | |
| JP2007523870A (ja) | ヒドロキシピリジンｃｇｒｐ受容体拮抗薬 | |
| JP2007525430A (ja) | ベノジアゼピンスピロヒダントインｃｇｒｐ受容体拮抗物質 | |
| CN101076527B (zh) | 三环酰苯胺螺乙内酰脲cgrp受体拮抗剂 | |
| JP2013542261A (ja) | ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト | |
| JP2010523663A (ja) | 第３級アミド、スルホンアミド、カルバミン酸及び尿素末端基をもつｃｇｒｐ受容体アンタゴニスト | |
| US8163737B2 (en) | CGRP receptor antagonists | |
| JP2008526984A (ja) | Ｃｇｒｐ受容体拮抗薬 | |
| JP2009515975A (ja) | 二環式スピロヒダントインｃｇｒｐ受容体アンタゴニスト | |
| JP2012502995A (ja) | 二環式ジヒドロイミダゾロンｃｇｒｐ受容体アンタゴニスト | |
| JP2006516647A (ja) | 新規置換２，３−ベンゾジアゼピン誘導体 | |
| HK1136555A (en) | Cgrp receptor antagonists | |
| HK1135384A (en) | Cgrp receptor antagonists | |
| HUP0400338A2 (en) | New substituted 2,3-benzodiazepine derivatives, their use and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100707 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130318 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130326 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130418 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130425 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130517 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130618 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140204 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140325 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5511379 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |